Want to see IN:IOLCP full AI Analyst Report?
Top Page
IOL Chemicals & Pharmaceuticals Ltd.
(IOLCP)
Select Model
Select Model
Rating:67Neutral
Price Target:
₹159.00
▲(89.08% Upside)
Action:Reiterated
Date:07/08/26
The score is driven primarily by strong technical momentum and trend strength, partially offset by mixed fundamentals where a conservative balance sheet is weighed down by weaker margin/ROE versus prior peaks and inconsistent free cash flow generation. Valuation is a notable headwind due to the high P/E and low dividend yield.
Positive Factors
Conservative balance sheet
Very low leverage and a growing equity base provide durable financial resilience. This conservatism supports capital spending, regulatory compliance and downturn tolerance without immediate financing needs, enabling long-term strategic execution and optionality.
Negative Factors
Material margin compression vs peak
Margins have contracted materially from earlier peaks, implying sustained pricing, mix or cost pressures. Lower gross and net margins reduce internal cash generation, weaken reinvestment capacity, and suggest structural competitiveness or input‑cost challenges that may persist.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and a growing equity base provide durable financial resilience. This conservatism supports capital spending, regulatory compliance and downturn tolerance without immediate financing needs, enabling long-term strategic execution and optionality.
Read all positive factors
IOL Chemicals & Pharmaceuticals Ltd. (IOLCP) vs. iShares MSCI India ETF (INDA)
Market Cap
₹46.86B
Dividend Yield0.64%
Average Volume (3M)113.78K
Price to Earnings (P/E)27.4
Beta (1Y)1.55
Revenue Growth18.56%
EPS Growth60.06%
CountryIN
Employees3,592
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4.69
Shares Outstanding293,527,500
10 Day Avg. Volume248,884
30 Day Avg. Volume113,785
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)1.19
Price to Sales (P/S)0.92
P/FCF Ratio55.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)6.1
Revenue Forecast (FY)₹25.66B
IOL Chemicals & Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Established in 1986 and headquartered in Ludhiana, India, IOL Chemicals and Pharmaceuticals Limited operates as a global manufacturer and supplier of diverse pharmaceutical and chemical products. Its pharmaceutical portfolio encompasses a wide arr...
How the Company Makes Money
IOLCP makes money primarily by manufacturing and selling (1) pharmaceutical APIs and (2) chemical products.
1) Pharmaceutical APIs revenue: The company generates revenue by producing APIs (notably Ibuprofen and other APIs) and selling them to ph...
IOL Chemicals & Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
82
Very Positive
Cash Flow
45
Neutral
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 23.19B | 20.68B | 21.19B | 22.02B | 21.84B |
| Gross Profit | 5.03B | 6.54B | 2.70B | 6.41B | 5.72B |
| EBITDA | 2.69B | 2.25B | 2.61B | 2.46B | 2.71B |
| Net Income | 1.38B | 1.01B | 1.34B | 1.39B | 1.68B |
Balance Sheet | |||||
| Total Assets | 25.87B | 23.82B | 22.44B | 20.22B | 19.62B |
| Cash, Cash Equivalents and Short-Term Investments | 2.02B | 2.09B | 1.43B | 186.40M | 1.20B |
| Total Debt | 1.35B | 1.17B | 327.60M | 798.10M | 439.50M |
| Total Liabilities | 7.88B | 6.94B | 6.33B | 5.14B | 5.70B |
| Stockholders Equity | 17.99B | 16.88B | 16.12B | 15.08B | 13.92B |
Cash Flow | |||||
| Free Cash Flow | 384.30M | -349.30M | 159.10M | -895.50M | -602.40M |
| Operating Cash Flow | 2.11B | 1.79B | 2.90B | 1.22B | 930.50M |
| Investing Cash Flow | -2.10B | -1.54B | -1.91B | -1.20B | -1.21B |
| Financing Cash Flow | -145.00M | 460.40M | -925.00M | -41.10M | -16.40M |
IOL Chemicals & Pharmaceuticals Ltd. Technical Analysis
Positive
84.09
Price Trends
150.24
Positive
125.78
Positive
102.73
Positive
Market Momentum
3.28
Positive
50.61
Neutral
17.31
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:IOLCP, the sentiment is Positive. The current price of 84.09 is below the 20-day moving average (MA) of 156.48, below the 50-day MA of 150.24, and below the 200-day MA of 102.73, indicating a bullish trend. The MACD of 3.28 indicates Positive momentum. The RSI at 50.61 is Neutral, neither overbought nor oversold. The STOCH value of 17.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:IOLCP.
IOL Chemicals & Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | ₹46.86B | 27.43 | ― | 0.97% | 18.56% | 60.06% | |
66 Neutral | ₹299.19B | 60.03 | ― | 0.18% | 78.33% | 182.61% | |
64 Neutral | ₹210.90B | 31.08 | ― | 0.18% | 24.83% | 36.88% | |
60 Neutral | ₹37.73B | 19.51 | ― | 0.24% | 10.54% | 1.29% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ₹26.80B | -78.14 | ― | 0.46% | -5.37% | -153.35% | |
46 Neutral | ₹26.17B | -982.23 | ― | ― | 15.49% | -108.86% |
* General Sector Average
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
157.00
60.31
62.37%
IN:AARTIDRUGS
Aarti Drugs Limited
408.50
-66.85
-14.06%
IN:GRANULES
Granules India Limited
838.10
378.01
82.16%
IN:HIKAL
Hikal Limited
214.45
-43.15
-16.75%
IN:NEULANDLAB
Neuland Laboratories Ltd.
23,296.85
9,604.81
70.15%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
549.90
-79.65
-12.65%
IOL Chemicals & Pharmaceuticals Ltd. Corporate Events
IOL Chemicals wins Chinese approval for Clopidogrel Bisulfate API
Jul 14, 2026
IOL Chemicals and Pharmaceuticals Ltd. has received approval from China’s National Medical Products Administration for its Clopidogrel Bisulfate active pharmaceutical ingredient. The clearance from the Centre for Drug Evaluation complements ...
IOL Chemicals & Pharmaceuticals Opens Special Window for Physical Share Demat and Backs Investor Campaign
Jun 19, 2026
IOL Chemicals Pharmaceuticals has announced a one-time special window to facilitate the transfer-cum-dematerialisation of physical shares where transfer deeds were executed before 1 April 2019, including previously rejected or unattended cases. T...
IOL Chemicals & Pharmaceuticals Publishes Audited FY26 Financial Results
May 21, 2026
IOL Chemicals Pharmaceuticals Ltd. published its audited standalone and consolidated financial results for the quarter and year ended 31 March 2026 in multiple leading business newspapers, in line with securities listing regulations. The results,...
IOL Chemicals Promoters Confirm No Encumbrance on Shares for FY 2026
May 4, 2026
Promoter Varinder Gupta has informed Indian stock exchanges that there are no encumbrances on the shares of IOL Chemicals Pharmaceuticals Ltd. held by him and the wider promoter group for the financial year ended 31 March 2026. The declaration, m...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.